Menotropins Disease Interactions

Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome. Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.

The use of menotropins is contraindicated in patients with uncontrolled non- gonadal endocrinopathies such as thyroid, adrenal or pituitary disorders.

The use of menotropins is contraindicated in patients with CNS lesions, such as pituitary gland or hypothalamus tumors. Menotropins possess LH and FSH activity.

The use of menotropins is contraindicated in female patients with abnormal vaginal bleeding of undetermined origin. Patients should be evaluated to ensure neoplastic lesions are not present. The use of menotropins is contraindicated in the presence of sex hormone dependent tumors of the reproductive tract or accessory organs.

Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins. Caution and monitoring is advised if used in women with pulmonary conditions.

Safety, efficacy and pharmacokinetics of menotropins have not been established in women with renal or hepatic insufficiency. Caution is advised.